292 related articles for article (PubMed ID: 31597699)
1. PLK1 targets NOTCH1 during DNA damage and mitotic progression.
De Blasio C; Zonfrilli A; Franchitto M; Mariano G; Cialfi S; Verma N; Checquolo S; Bellavia D; Palermo R; Benelli D; Screpanti I; Talora C
J Biol Chem; 2019 Nov; 294(47):17941-17950. PubMed ID: 31597699
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
3. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
Ergul M; Bakar-Ates F
Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A.
Jang YJ; Ji JH; Choi YC; Ryu CJ; Ko SY
J Biol Chem; 2007 Jan; 282(4):2473-82. PubMed ID: 17121863
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
[TBL] [Abstract][Full Text] [Related]
6. FRET-Based Sorting of Live Cells Reveals Shifted Balance between PLK1 and CDK1 Activities During Checkpoint Recovery.
Lafranchi L; Müllers E; Rutishauser D; Lindqvist A
Cells; 2020 Sep; 9(9):. PubMed ID: 32961751
[TBL] [Abstract][Full Text] [Related]
7. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
8. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase.
Yuan JH; Feng Y; Fisher RH; Maloid S; Longo DL; Ferris DK
Mol Cancer Res; 2004 Jul; 2(7):417-26. PubMed ID: 15280449
[TBL] [Abstract][Full Text] [Related]
10. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint.
van Vugt MA; Gardino AK; Linding R; Ostheimer GJ; Reinhardt HC; Ong SE; Tan CS; Miao H; Keezer SM; Li J; Pawson T; Lewis TA; Carr SA; Smerdon SJ; Brummelkamp TR; Yaffe MB
PLoS Biol; 2010 Jan; 8(1):e1000287. PubMed ID: 20126263
[TBL] [Abstract][Full Text] [Related]
11. MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells.
Wang XH; Lu Y; Liang JJ; Cao JX; Jin YQ; An GS; Ni JH; Jia HT; Li SY
Biochem Biophys Res Commun; 2016 Sep; 478(2):676-82. PubMed ID: 27498003
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora.
Bruinsma W; Aprelia M; García-Santisteban I; Kool J; Xu YJ; Medema RH
Oncogene; 2017 Mar; 36(13):1840-1848. PubMed ID: 27721411
[TBL] [Abstract][Full Text] [Related]
13. NFBD1/MDC1 is phosphorylated by PLK1 and controls G2/M transition through the regulation of a TOPOIIα-mediated decatenation checkpoint.
Ando K; Ozaki T; Hirota T; Nakagawara A
PLoS One; 2013; 8(12):e82744. PubMed ID: 24349352
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1 inhibits DNA damage response during mitosis.
Benada J; Burdová K; Lidak T; von Morgen P; Macurek L
Cell Cycle; 2015; 14(2):219-31. PubMed ID: 25607646
[TBL] [Abstract][Full Text] [Related]
15. RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point.
Ergul M; Bakar-Ates F
Anticancer Agents Med Chem; 2019; 19(15):1846-1854. PubMed ID: 31244432
[TBL] [Abstract][Full Text] [Related]
16. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
Shtivelman E
Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
[TBL] [Abstract][Full Text] [Related]
17. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
19. Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis.
Cialfi S; Palermo R; Manca S; De Blasio C; Vargas Romero P; Checquolo S; Bellavia D; Uccelletti D; Saliola M; D'Alessandro A; Zolla L; Gulino A; Screpanti I; Talora C
Cell Cycle; 2014; 13(13):2046-55. PubMed ID: 24801890
[TBL] [Abstract][Full Text] [Related]
20. PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Su S; Chhabra G; Ndiaye MA; Singh CK; Ye T; Huang W; Dewey CN; Setaluri V; Ahmad N
Mol Cancer Ther; 2021 Jan; 20(1):161-172. PubMed ID: 33177155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
